Discussion - Multiple Myeloma

ENG

remnant, IFM2021-01 teclille

ASH 2025

Which treatment strategy in NDMM? Is immunotherapy…

H. Einsele, H. Hashmi, B. C. Lipe, M. Merz, F. Schjesvold

ENG

iMMagine--1, inMMyCAR

ASH 2025

Advances in CAR T cell therapy: new constructs,…

H. Einsele, H. Hashmi, B. C. Lipe, M. Merz, F. Schjesvold

ENG

Majestec-3, CARTITUDE-4

ASH 2025

Strategies and perspectives for r/r MM: Significance of…

H. Einsele, H. Hashmi, B. C. Lipe, M. Merz, F. Schjesvold

Relapsed/Refractory Multiple Myeloma

ENG

CARTITUDE-4

ASH 2025

Long-term PFS benefit with cilta-cel in RRMM

Brea C. Lipe, MD

ENG

iMMagine--1

ASH 2025

Anitocel challenges ciltacel

Maximillian Merz, MD

ENG

majestec-3

ASH 2025

Tec-Dara as a new Standard in 2nd line

Katja Weisel, MD

ENG

Majestec-3

ASH 2025

Dara / Tecli - the new SOC for first relapse with MM

Hamza Hashmi, MD

ENG

ASH 2025

Still work to do

Brea C. Lipe, MD

ENG

Majestec-3, inMMyCAR

ASH 2025

New gamechanging therapy options

C. Ola Landgren, MD

ENG

inMMyCAR

ASH 2025

In vivo CARs are coming

Fredrik Schjesvold, MD

ENG

ASH 2025

MMR vaccination in MM patients receiving daratumumab…

Brea C. Lipe, MD

ENG

redirectt-1

ASH 2025

Talquetamab + Teclistamab meet the unmet need for an…

Hamza Hashmi, MD

ENG

CARTITUDE-4, Majestec-3, inMMyCAR, iMMagine-1

ASH 2025

Strategies and perspectives for multiple myeloma

Hermann Einsele, MD

ENG

Majestec-3

ASH 2025

Bispecifics in 2nd-line treatment

Fredrik Schjesvold, MD

ENG

redirectt-1

ASH 2025

Talquetamab + Teclistamab in extramedullary disease

Katja Weisel, MD

ENG

Majestec-3

ASH 2025

Majestec-3: the best myeloma abstract at ASH 2025

Maximillian Merz, MD

ENG

redirectt-1

ASH 2025

Dual targeting for high risk myeloma

Maximillian Merz, MD

ENG

CARTITUDE-4

ASH 2025

Is CAR T as good as Dara / Tecli?

Hamza Hashmi, MD

Relapsed/Refractory Multiple Myeloma – multi language

GER

redirectt-1

ASH 2025

Talquetamab + Teclistamab bei extramedullärer…

Katja Weisel, MD

GER

majestec-3

ASH 2025

Tec-Dara als neuer Standard in der Zweitlinie

Katja Weisel, MD

GER

CARTITUDE-4, Majestec-3, inMMyCAR, iMMagine-1

ASH 2025

Strategien und Perspektiven beim Multiplen Myelom

Hermann Einsele, MD

NOR

Majestec-3

ASH 2025

Bispesifikke i andrelinje

Fredrik Schjesvold, MD

GER

redirectt-1

ASH 2025

Dual-targeting beim Hochrisiko-Myelom

Maximillian Merz, MD

GER

iMMagine--1

ASH 2025

Anitocel macht Ciltacel Konkurrenz

Maximillian Merz, MD

NOR

inMMyCAR

ASH 2025

In vivo CARs er på vei

Fredrik Schjesvold, MD

SWE

Majestec-3, inMMyCAR

ASH 2025

Nya banbrytande behandlingsalternativ

C. Ola Landgren, MD

GER

Majestec-3

ASH 2025

Majestec-3: Der beste Abstract zum Multiplen Myelom…

Maximillian Merz, MD

Newly Diagnosed Multiple Myeloma

ENG

IFM2021-01 teclille

ASH 2025

Is Dar-Tec better than DRD or DVRD for TIE NDMM?

Hamza Hashmi, MD

ENG

AURIGA

ASH 2025

Importance of DaraLen maintenance after ASCT

Katja Weisel, MD

Newly Diagnosed Multiple Myeloma – multi language

GER

AURIGA

ASH 2025

Bedeutung der DaraLen-Erhaltungstherapie nach ASCT

Katja Weisel, MD

MGUS & Smoldering Myeloma

ENG

GEM-CESAR

ASH 2025

Are we curing SMM?

Brea C. Lipe, MD

Discussion – Chronic/Small Lymphocytic Leukemia

ENG

CLL17, CaDAnCe-101

ASH 2025

Advances in CLL therapy: BTK inhibitors, fixed-duration…

M. Dreyling, T. Eyre

Chronic/Small Lymphocytic Leukemia

ENG

CLL17

ASH 2025

Primary results from CLL17

Toby Eyre, MD

ENG

BRUIN CLL-313

ASH 2025

Pirto superior to BR

Martin Dreyling, MD

ENG

BRUIN LOXO-BTK-18001 BRUIN CLL-321

ASH 2025

Pirtobrutinib as 2L therapy after cBTKi in CLL

Toby Eyre, MD

Chronic/Small Lymphocytic Leukemia – multi language

GER

BRUIN CLL-313

ASH 2025

Pirtobrutinib ist BR signifikant überlegen bei CLL

Martin Dreyling, MD

Discussion – Aggressive Non-Hodgkin-Lymphoma

ENG

R-Pola-Glo, EPCORE DLBCL-3

ASH 2025

Bispecifics and CAR T: are we entering a new era for…

M. Dreyling, M. Jerkeman, S. Ferrero, C. Thieblemont

Aggressive Non-Hodgkin-Lymphoma

ENG

ASH 2025

Zanubrutinib and high-dose methotrexate in primary CNS…

Mats Jerkeman, MD

ENG

DALY 2-EU

ASH 025

Zamto-cel in r/r DLBCL patients, who are not eligible…

Mats Jerkeman, MD

Aggressive Non-Hodgkin-Lymphoma – multi language

SWE

DALY 2-EU

ASH 2025

Zamto-cel för patienter med recidiverande DLBCL, inte…

Mats Jerkeman, MD

SWE

ASH 2025

Zanubrutinib och högdos metotrexat för primärt…

Mats Jerkeman, MD

Discussion – Indolent Non-Hodgkin-Lymphoma

ENG

window-3, TrAVeRse, GLOVe

ASH 2025

Integrating targeted agents and cellular therapy in…

M. Dreyling, T. Eyre, M. Jerkeman, S. Ferrero, C. Sarkozy, C. Thieblemont

ENG

ROSEWOOD, MorningSun, EPCORE FL-1, TRANSCEND FL

ASH 2025

Therapeutic innovations in FL: is cure within reach?…

M. Dreyling, T. Eyre, M. Jerkeman, S. Ferrero, C. Thieblemont, C. Sarkozy

ENG

BRUIN, rock-1

ASH 2025

Targeting BTK and BCL-2: where do we go in r/r MCL?

M. Dreyling, T. Eyre, M. Jerkeman, S. Ferrero, C. Sarkozy, C. Thieblemont

Follicular Lymphoma

ENG

MorningSun study

ASH 2025

12 month follow-up of MorningSun for HTB FL - SC…

Simone Ferrero, MD

ENG

EPCORE FL-1

ASH 2025

Epcoritamab + R2 for 2L treatment in r/r follicular…

Mats Jerkeman, MD

ENG

EPCORE FL-1

ASH 2025

Primary results of EPCORE FL-1 trial in r/r FL

Simone Ferrero, MD

ENG

ROSEWOOD

ASH 2025

Final results from phase II trial ROSEWOOD in r/r FL

Simone Ferrero, MD

ENG

EPCORE FL-1

ASH 2025

Outstanding primary results of EPCORE FL-1

Toby Eyre, MD

ENG

TRANSCEND FL

ASH 2025

3 year clinical update of liso-cel in r/r FL

Simone Ferrero, MD

ENG

epcore FL-1

ASH 2025

E+R² as the new standard for r/r FL

Martin Dreyling, MD

Follicular Lymphoma – multi language

ITA

TRANSCEND FL

ASH 2025

Aggiornamento clinico a 3 anni del trial…

Simone Ferrero, MD

ITA

MorningSun study

ASH 2025

Aggiornamento clinico a 12 mesi del trial "MorningSun"…

Simone Ferrero, MD

SWE

EPCORE FL-1

ASH 2025

Epcoritamab + R2 som 2:a linjens behandling vid…

Mats Jerkeman, MD

ITA

EPCORE FL-1

ASH 2025

Risultati preliminari del trial di fase III "EPCORE…

Simone Ferrero, MD

GER

epcore FL-1

ASH 2025

Bispezifischer AK Epcoritamab + R² neuer Standard beim…

Martin Dreyling, MD

ITA

ROSEWOOD

ASH 2025

Risultati finali del trial di fase II ROSEWOOD per…

Simone Ferrero, MD

Mantle Cell Lymphoma

ENG

ASH 2025

Glofitamab + Len+ Ven in 1L high-risk MCL (GLOVe)

Mats Jerkeman, MD

ENG

window-3

ASH 2025

Window-3: 1L treatment in high risk MCL - effective but…

Clementine Sarkozy, MD, PhD

ENG

TrAVeRse

ASH 2025

AVR, the next step in therapy-evolution of MCL

Martin Dreyling, MD

ENG

ASH 2025

BOVEN is doable für in elderly patients

Clementine Sarkozy, MD, PhD

ENG

TrAVeRse

ASH 2025

TrAVeRse: a triplet as 1L for allcomers!

Clementine Sarkozy, MD, PhD

ENG

ASH 2025

GLOVe: a bispec in 1L for high risk MCL

Clementine Sarkozy, MD, PhD

ENG

BGB-11417-201

ASH 2025

Sonrotoclax monotherpay in R/R MCL

Toby Eyre, MD

ENG

ASH 2025

Boven in older MCL patients

Toby Eyre, MD

Mantle Cell Lymphoma – multi language

FRA

window-3

ASH 2025

Window-3 chez les sujets de hauts risques en première…

Clementine Sarkozy, MD, PhD

FRA

TrAVeRse

ASH 2025

TrAVeRse, une triplette en première ligne d’un LCM pour…

Clementine Sarkozy, MD, PhD

GER

TrAVeRse

ASH 2025

AVR nächster Schritt in der Therapieevolution beim MCL

Martin Dreyling, MD

FRA

ASH 2025

GLOVe: un bispécifique en première ligne pour les LCM…

Clementine Sarkozy, MD, PhD

FRA

ASH 2025

BOVEN est faisable chez les sujets âges en première…

Clementine Sarkozy, MD, PhD

SWE

ASH 2025

Glofitamab + Len+ Ven som primärbehandling vid högrisk…

Mats Jerkeman, MD